TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05255666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 400 mg intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Irinotecan
Description: Starting at 50 mg/m\^2. The dose may be increased to 70 mg/m\^2 if tolerated or dose reduced to 35 mg/m\^ if treatment-emergent severe adverse event (TESAE) occurs.
Study: NCT05628727

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5:2 Fasting
Description: This group will use the 5:2 method and fast for two non-consecutive days of the week.
Study: NCT06041802

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MK-3475A
Description: MK-3475A is a fixed-dose formulation of pembrolizumab and MK-5180 for SC administration.
Study: NCT05133037

Intervention type: DEVICE
Intervention: GE MR Scanner
Description: 3T GE MR 750 systems MR scanner~Scanners run compatible software so pulse sequences and reconstructions can easily be supported on all systems. Reconstruction servers are networked to all scanners for reconstruction and data archiving. 3T scanner is equipped with state-of-the-art gradient systems (at least 40 mT/m Gradients / 150 mT/m/ms slew rates) and 16 or more receive channels. 3T scanner includes an assortment of RF coils including quadrature and phased-array coils designed to image brain, spine, neurovascular, torso, pelvis, cardiac, knee, foot/ankle, and hand/wrist. 3T system has several sizes of 16-channel wrap coils that are excellent for scans using parallel imaging.
Study: NCT06466473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin (Ascoli)
Description: Phenytoin 50mg chewable tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenytoin (Vega Baja)
Description: Phenytoin 50mg chewable tablets
Study: NCT06536036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SIM0270
Description: Use according to the prescribed protocol
Study: NCT06640621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Different concentration of ropivacaine for single brachial plexus block
Description: 40 ASA grade I - II patients were selected from the patients who underwent shoulder ligament rupture repair surgery under selective general anesthesia combined with brachial plexus block analgesia in the sports medical center of our hospital. They were randomly divided into two groups: high concentration group (group I) and low concentration group (Group II), with 20 cases in each group. 40 patients underwent a single brachial plexus block under ultrasound guidance before general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Different concentration of ropivacaine for single brachial plexus block
Description: 40 ASA grade I - II patients were selected from the patients who underwent shoulder ligament rupture repair surgery under selective general anesthesia combined with brachial plexus block analgesia in the sports medical center of our hospital. They were randomly divided into two groups: high concentration group (group I) and low concentration group (Group II), with 20 cases in each group. 40 patients underwent a single brachial plexus block under ultrasound guidance before general anesthesia.
Study: NCT06638489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Intensity-Focused-Electromagnetic-Therapy (HIFEM)
Description: The HIFEM stimulation was administered using an Emsella instrument (manufactured by BTL Industry Inc., Boston, MA). The frequency ranged between 50 and 60Hz, and the intensity was as high as the patient could tolerate, which was usually up to 100%.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic-Floor-Muscle-Training (PFMT)
Description: The PFMT protocol was that outlined by previous study. The participants were instructed to execute 5 rapid contractions over a span of 3 seconds and 10 prolonged contractions, each lasting between 3 to 8 seconds, with intervals of 10 seconds for relaxation in between, all while in a crook-lying position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic-Floor-Muscle-Training (PFMT)
Description: The PFMT protocol was that outlined by previous study. The participants were instructed to execute 5 rapid contractions over a span of 3 seconds and 10 prolonged contractions, each lasting between 3 to 8 seconds, with intervals of 10 seconds for relaxation in between, all while in a crook-lying position.
Study: NCT06642766

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fiber supplement
Description: Subjects that meet the inclusion criteria and with symptoms appropriate for fiber supplementation are eligible to participate. Participants will be instructed to use the fiber product (NutraLieve) as currently labeled; start with a dosage of 4-5 grams per day (one heaping teaspoon), initially taken once daily, increasing up to 3 heaping teaspoons a day (maximum dose 15 grams/day) on an as needed basis.Participants will be prospectively assessed for symptoms at baseline and at 6 weeks.~* The primary endpoint, number of bowel movements, will be assessed by bowel movements in the last 72-hour period at baseline and at 6 weeks, by patient recall/diary.~* Secondary endpoints, reduction in bloating or gas, or any adverse events will be assessed using analog scales, also by 72-hour recall at baseline and at 6 weeks, by patient recall/diary.
Study: NCT06639893

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telescopic overdenture
Description: Telescopic overdenture with two dental implants in intraforaminal area for mandible.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telescopic overdenture
Description: Telescopic overdenture with two dental implants in intraforaminal area for mandible.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Telescopic overdenture
Description: Telescopic overdenture with two dental implants in intraforaminal area for mandible.
Study: NCT05549622

Intervention type: OTHER
Group type: OTHER
Intervention: Low-soluble fiber diet
Description: 12 older adults (\>65y) will be randomized to consume the USDA Guidelines for fiber intake (10g of total fiber/1000 calories), as the low-soluble fiber diet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-soluble fiber diet
Description: 12 older adults (\>65y) will be randomized to consume 34-35g of total fiber/1000 calories, as the high-soluble fiber diet
Study: NCT06642038

Intervention type: PROCEDURE
Intervention: Transbronchial Endoscopic Thermal Vapor Ablation
Description: Transbronchial Endoscopic Thermal Vapor Ablation
Study: NCT05231915

Intervention type: GENETIC
Group type: OTHER
Intervention: HOXB13 c.853delT mutation
Description: Identify the Allelic frequency of the HOXB13 c.853delT mutation in patients with a cancer prostate in Martinique
Study: NCT06639230

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: laser therapy
Description: Laser-treated group (test group): This group consisted of ten patients treated using diode lasers. The diode laser was operated in continuous wave mode with an output power of 3 W in contact mode to excise the pyogenic granuloma. The tip was moved around the base of the lesion in circles. The base of the lesion was cut precisely till the whole mass was entirely excised.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sclerotherapy
Description: Sclerotherapy-treated group (control group): This group consisted of ten patients treated with injections of sclerosing agent. After anaesthetizing the surgical site with a local anesthetic agent, The lesion was injected with a 2.5% concentration until it leaked out from the surface, leading to necrosis and spontaneous detachment of the lesion.
Study: NCT06642597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incremental PD
Description: Incremental PD: Commence PD using goal-directed PD prescription ≤14 exchanges/week for continuous ambulatory PD (CAPD) or ≤21 exchanges/week for automated PD (APD) with no day dwell until an indication for increase in the PD dose (trigger point) is reached.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full dose PD
Description: Full dose PD: Commence with 24 hours, 7 days/week PD (i.e., CAPD ≥28 exchanges/week or APD (overnight) with day dwell (i.e., no dry abdomen)).
Study: NCT05597124

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardio-Dance Fitness
Description: This is an aerobic cardio-dance fitness exercise class in a social context with aerobic intensity assessed by heart rate monitoring throughout the class. Participants will meet three times a week for approximately 60 minutes per session, over 24 weeks (approximately 6 months).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strength, Flexibility & Balance
Description: This intervention will serve as a stringent, structurally equivalent, active comparator to the CDF intervention, identical in duration, frequency, and social contact except for the content of this non-aerobic intervention. SFB will involve non-aerobic activity with strength, flexibility, and balance training.
Study: NCT05989269

Intervention type: OTHER
Group type: OTHER
Intervention: Modified lab reporting
Description: If appropriateness of culturing i.e., clinical criteria for pneumonia testing does not meet the algorithm AND there is growth of one or more organism(s) that are not considered normal upper respiratory flora, during the intervention period, the result will be modified to reflect the likelihood of asymptomatic colonization.
Study: NCT05824728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGB101
Description: low-dose levetiracetam, 220 mg, extended release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGB101
Description: low-dose levetiracetam, 220 mg, extended release tablet
Study: NCT06539442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Versius Surgical System
Description: Urological minimal access surgery performed with Versius Surgical System
Study: NCT04940546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Mode of administration: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Mode of administration: Intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Mode of administration: Orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Mode of administration: Intravenously
Study: NCT05048355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Power Knee Mainstream Dynamic
Description: Powered Microprocessor controlled prosthetic knee. The Power Knee Mainstream - Dynamic, was designed to provide powered swing dynamics to restore muscle activity and thereby attempting to mitigate this increase in metabolic cost that individuals living with TF amputation face.
Study: NCT05413421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-944
Description: Oral, once daily, continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-944
Description: Oral, once daily, continuous
Study: NCT05048355

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive microprocessor controlled knee
Description: Any passive microprocessor controlled prosthetic knee on the market
Study: NCT05464108

Intervention type: DIAGNOSTIC_TEST
Intervention: The diagnosis of Artificial Intelligence and endosopists
Description: Endosopists and AI will assess the EGGIM score independently when the patients is eligible. In addition, they can not see the OLGIM score of the patients.
Study: NCT05508360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PerQdisc Nucleus Replacement System
Description: Lumbar spine disc nucleus replacement system. All patients meeting all inclusion criteria and no exclusion criteria will be considered for nucleus replacement surgery following a review by the Medical Advisory Board.
Study: NCT05413421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORIC-944
Description: Oral, once daily, continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate (Zytiga®) 250 mg or 500 mg tablets
Description: Oral, 1000 mg once daily, continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide (Erleada™) 60 mg or 240 mg tablets
Description: Oral, 240 mg once daily, continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide (Erleada™) 60 mg or 240 mg tablets
Description: Oral, 240 mg once daily, continuous
Study: NCT04499131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Subjects will undergo an artificial cycle with hormone replacement therapy (HRT) with the aim of comparing the endometrial gene expression profile in the different types of exogenous progesterone with different doses and routes of administration.
Study: NCT05413421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (Nubeqa®) 300 mg tablets
Description: Oral, 600 mg twice daily, continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (Nubeqa®) 300 mg tablets
Description: Oral, 600 mg twice daily, continuous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide (Xtandi®) 40 mg capsules or 40 mg and 80 mg tablets
Description: Oral, 160 mg once daily, continuous
Study: NCT06019585

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Splint inmmobilization
Description: After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with a plaster splint of París for 3 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bandage immovilization
Description: After internal fixation with volar locking plate, groups of distal radius fractures are inmobilized with compressive bandage for 3 weeks
Study: NCT06345092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: addition of vitamin C to IPRF

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Injectable platelet rich fibrin
Description: injection of IPRF alone

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injectable platelet rich fibrin
Description: injection of IPRF alone
Study: NCT04965766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: U3-1402
Description: U3-1402 is uniquely designed to target HER3-a receptor that contributes to treatment resistance and poor prognosis in hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer patients. This drug is distinct from other interventions due to its composition as an antibody-drug conjugate (ADC): a monoclonal antibody against HER3 conjugated to a topoisomerase I inhibitor, which specifically targets HER3-overexpressing tumor cells. The drug is delivered via a cleavable linker that allows for controlled release of the chemotherapeutic agent within the cancer cells, minimizing systemic side effects.
Study: NCT06664606

Intervention type: BEHAVIORAL
Intervention: Pain Neuroscience Education Program (PNE)
Description: The Pain Neuroscience Education (PNE) Program is a structured educational intervention aimed at primary school students with and without intellectual disabilities. This program introduces students to basic concepts of pain neuroscience, designed to increase understanding of pain mechanisms and promote healthy pain coping strategies. The intervention was adapted to 'easy reading' format to ensure accessibility for students with intellectual disabilities, and was delivered in both rural and urban school settings in Extremadura, Spain.

Intervention type: BEHAVIORAL
Intervention: Pain Neuroscience Education Program (PNE)
Description: The Pain Neuroscience Education (PNE) Program is a structured educational intervention aimed at primary school students with and without intellectual disabilities. This program introduces students to basic concepts of pain neuroscience, designed to increase understanding of pain mechanisms and promote healthy pain coping strategies. The intervention was adapted to 'easy reading' format to ensure accessibility for students with intellectual disabilities, and was delivered in both rural and urban school settings in Extremadura, Spain.

Intervention type: BEHAVIORAL
Intervention: Pain Neuroscience Education Program (PNE)
Description: The Pain Neuroscience Education (PNE) Program is a structured educational intervention aimed at primary school students with and without intellectual disabilities. This program introduces students to basic concepts of pain neuroscience, designed to increase understanding of pain mechanisms and promote healthy pain coping strategies. The intervention was adapted to 'easy reading' format to ensure accessibility for students with intellectual disabilities, and was delivered in both rural and urban school settings in Extremadura, Spain.

Intervention type: BEHAVIORAL
Intervention: Pain Neuroscience Education Program (PNE)
Description: The Pain Neuroscience Education (PNE) Program is a structured educational intervention aimed at primary school students with and without intellectual disabilities. This program introduces students to basic concepts of pain neuroscience, designed to increase understanding of pain mechanisms and promote healthy pain coping strategies. The intervention was adapted to 'easy reading' format to ensure accessibility for students with intellectual disabilities, and was delivered in both rural and urban school settings in Extremadura, Spain.
Study: NCT06662942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: StrataMGT
Description: StrataMGT® is a semi-permeable, non-resorbable and self-drying gel. StrataMGT® contains no steroids, hormones, alcohol, parabens or fragrances. StrataMGT® gel is bacteriostatic, inert, and is manufactured in compliance with good manufacturing practices (GMPs), 21CFR210 and 211.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a sterile, transparent, water-soluble lubricating jelly that is not silicone-based. It will be applied topically to the vulvar skin.
Study: NCT06666036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Connect
Description: Community level enhancements
Study: NCT06277492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Single ascending doses SUL-238
Description: PART 1: SUL-238 single ascending doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single dose Placebo
Description: PART 1: Placebo single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose SUL-238
Description: PART 2: SUL-238 single dose for pharmacokinetics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Multiple ascending doses SUL-238
Description: PART 3: SUL-238 multiple ascending doses
Study: NCT05858736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI-061
Description: A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC- 392 (Anti-CTLA-4) Antibodies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AI-061
Description: A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC- 392 (Anti-CTLA-4) Antibodies.
Study: NCT06277492

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple doses Placebo
Description: PART 3: Placebo multiple doses
Study: NCT05995600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiplatelet Drug
Description: Clopidogrel ± other antiplatelet drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin (target prothrombin time-international normalized ratio 2.0-3.0)
Study: NCT03845036

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH Diet plus Home-Based Exercise
Description: The DASH dietary program consists of a diet emphasizing foods rich in fruits, vegetables, whole grains, and low-fat dairy, in which patients record daily servings of fruits and vegetables. The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home-Based Exercise
Description: The home-based exercise program consists of intermittent walking to moderate claudication pain 3 times per week for 3 months in a home-based setting.
Study: NCT05620134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK08
Description: Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK08
Description: Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK08
Description: Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JK08
Description: Recombinant fusion protein consisting of two functional elements, which are a fully human monoclonal antibody, directed against CTLA-4 and a protein complex formed by the human IL-15 and the Sushi domain of human IL-15Rα.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immune checkpoint inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Immune checkpoint inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib Pill
Description: Multi-kinase inhibitor
Study: NCT05149872

Intervention type: OTHER
Group type: OTHER
Intervention: Muscle relaxation
Description: Rocuronium will be used to induce partial paralysis
Study: NCT06277492

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2000 mg SUL-238 single dose for pharmacokinetics (food effect)
Description: PART 2B: 2000 mg single dose of SUL-238

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single dose placebo (food effect)
Description: PART 2B: Placebo single dose
Study: NCT05098704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel treatment
Description: 75 mg daily during 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 75 mg daily during 24 months
Study: NCT06609512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide
Description: Oral Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enlicitide
Description: Oral Tablet
Study: NCT06665672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist worn vibro-acoustic device
Description: The Apollo device is a wrist worn device that is similar to a typical wristwatch. It emits a vibration pattern based on settings selected on a designated mobile app.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist worn vibro-acoustic device
Description: The Apollo device is a wrist worn device that is similar to a typical wristwatch. It emits a vibration pattern based on settings selected on a designated mobile app.